Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1617 1627
This examiner grants 61% of resolved cases
Sarah Pihonak is an examiner in Tech Center 1600 and Art Unit 1617. The examiner has a high volume of 1510 resolved cases and an allowance rate of 61.3 percent. This indicates a moderate but consistent likelihood of success. The median days to allowance is 1028, which provides a timeline for the expected duration of prosecution. With 1510 resolved cases, the data is very robust.
The interview lift for this examiner is 42.6 percent. This is an exceptionally high lift, suggesting that interviews are a critical factor in achieving an allowance compared to the 61.3 percent baseline. Practitioners should make interviews a primary strategy to take advantage of the 42.6 percent increase in success probability. The 1028 median days to allowance is a key factor for planning in Art Unit 1617. Overall, the 61.3 percent allowance rate and the 42.6 percent interview lift suggest that proactive engagement is highly effective across the 1510 resolved cases.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18579786 | COMPOSITIONS COMPRISING CONSTITUENTS, DERIVATIVES OR EXTRACTS OF CANNABIS | Non-Final OA | Nicoventures Trading Limited |
| 18035578 | A Method of Treating Depression by Immune Modulation | Non-Final OA | The University of British Columbia |
| 18237360 | METALLOENZYME MODULATORS | Non-Final OA | Regents of the University of Minnesota |
| 18548797 | METHOD OF INCREASING THE POPULATION OF BLAUTIA SPP. IN THE GUT MICROBIOME | Non-Final OA | DSM IP Assets B.V. |
| 18265660 | Method and Composition for Treating Pulmonary Fibrosis | Final Rejection | MANNKIND CORPORATION |
| 18841478 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | Non-Final OA | Agios Pharmaceuticals, Inc. |
| 18016262 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO INJURED KIDNEY | Final Rejection | Programmable Medicine Operating Company |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy